Showing results (171-180 of 192) with videos related to

Sort By:
Pageof 20
Cancer Cell|April 24, 2026
JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1G2032R resistance mutation in NSCLC: The first-in-human phase 1 trialYuxiang Ma, Jinhui Xue, Fangfang Gao, et al.
The Lancet. Gastroenterology & Hepatology|December 4, 2025
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trialsJian Li, Zhenghang Wang, Jing Huang, et al.
BMC Cancer|December 16, 2023
Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter studyXinlong Zheng, Longfeng Zhang, Lin Wu, et al.
Pain and Therapy|January 29, 2022
Pharmacist-Led Management Improves Treatment Adherence and Quality of Life in Opioid-Tolerant Patients With Cancer Pain: A Randomized Controlled TrialXiaowei Zheng, Haiying Ding, Silu Xu, et al.
Therapeutic Advances in Medical Oncology|August 7, 2024
Pretreatment pulmonary tumor necrosis is a promising prognostic imaging biomarker for first-line anti-PD-1/PD-L1 therapy in advanced lung squamous cell carcinoma: a multi-institutional, propensity score-matching cohort analysisQiaofeng Zhong, Longfeng Zhang, Lin Wu, et al.
Nature Medicine|January 6, 2025
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trialYuankai Shi, Jian Fang, Ligang Xing, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2025
Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 studyZhengbo Song, Ziming Li, Yiping Zhang, et al.
Cancer|August 2, 2024
Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody-drug conjugates-induced interstitial lung disease/pneumonitis: An expert consensus in ChinaChunwei Xu, Zhanhong Chen, Yuanli Xia, et al.
Thoracic Cancer|October 21, 2022
Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitorWenxian Wang, Qian Wang, Chunwei Xu, et al.
Thoracic Cancer|November 29, 2022
Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancerShirong Zhang, Wenxian Wang, Chunwei Xu, et al.
Pageof 20